Sickle Cell Disease (SCD) Treatment in India
- Top Accredited Hospitals
- Global Medical Standards
- Cutting-Edge Technology
- Proven Treatment Options
- High Success Rate
- Trusted by Millions
What is a Sickle Cell Disease (SCD)?
Sickle cell disease (SCD) is a group of inherited blood disorders caused by abnormal hemoglobin, most commonly hemoglobin S. The abnormal hemoglobin can cause red blood cells to become rigid and sickle-shaped, making them more likely to break down prematurely and block small blood vessels. This can lead to anemia, painful vaso-occlusive crises and progressive damage to organs such as the lungs, kidneys, brain, bones and spleen. SCD is inherited when a child receives disease-causing hemoglobin variants from their parents.
What is the Importance of Timely Treatment?
Timely diagnosis and comprehensive treatment can help reduce painful crises, prevent complications and protect organ function. Regular monitoring allows doctors to identify anemia, infection, stroke risk, kidney problems, eye complications and other effects of SCD at an earlier stage. Disease-modifying medicines, transfusion programmes, vaccination and preventive care can reduce complications, while selected patients with severe disease may be evaluated for hematopoietic stem-cell transplantation or gene therapy.
What are the Common Symptoms of Sickle Cell Disease (SCD)?
- Episodes of severe pain, known as vaso-occlusive crises
- Chronic or recurrent anemia
- Fatigue and weakness
- Shortness of breath
- Pale skin or yellowing of the eyes
- Swelling of the hands and feet, particularly in young children
- Frequent infections
- Delayed growth or puberty in some children
- Bone and joint pain
- Abdominal pain
- Vision problems
- Symptoms related to stroke or neurological complications
- Priapism in some males
- Chronic organ-related complications in severe disease
Causes and Risk Factors of Sickle Cell Disease (SCD)
Causes
- Sickle cell disease is caused by inherited changes in the HBB gene, which provides instructions for producing beta-globin, a component of hemoglobin.
- Different combinations of abnormal hemoglobin genes can produce different forms of SCD.
- The most severe and common form, HbSS, generally occurs when a child inherits a sickle hemoglobin gene from both parents.
Risk Factors
- Having parents who carry sickle hemoglobin or another disease-causing hemoglobin variant
- Family history of sickle cell disease
- Inheriting two disease-causing hemoglobin variants
- Genetic ancestry associated with a higher prevalence of sickle hemoglobin, including parts of Africa, the Middle East, the Mediterranean, South Asia and other regions
- Lack of access to early screening and comprehensive SCD care, which can increase the risk of preventable complications
Latest Research and Technologies in the Treatment of Sickle Cell Disease (SCD) in India
- Sickle cell treatment is increasingly moving toward disease-modifying and potentially curative approaches. Hydroxyurea remains an important therapy for reducing sickling and complications, while blood transfusion programmes are used for selected patients. Hematopoietic stem-cell transplantation can provide a potential cure for appropriately selected patients, particularly those with severe disease and a suitable donor. Gene therapies have introduced another potential curative approach. These therapies require specialised cell collection, conditioning treatment and long-term monitoring and are currently intended for carefully selected patients.
Treatment options for Sickle Cell Disease (SCD)
Blood Transfusion Therapy: Red blood-cell transfusions may be used to treat severe anemia or prevent or manage selected complications such as stroke. Long-term transfusion programmes require monitoring for iron overload and other transfusion-related complications.
Stem-Cell Transplantation : Allogeneic hematopoietic stem-cell transplantation can potentially cure SCD in selected patients. Suitability depends on factors such as disease severity, organ health, age, donor availability and the risks associated with transplantation.
Cost Start From 11500Explore Options
Gene Therapy: Selected patients with severe SCD may be evaluated for autologous gene-based therapies. These approaches involve collecting the patient's own blood-forming stem cells, modifying them in a specialised laboratory and returning them after conditioning treatment.
- Clinical assessment:
- Medical and Hematological Evaluation: A detailed history is taken to assess pain crises, fatigue, anemia, infections, transfusion history, jaundice, breathing problems, neurological symptoms, vision changes, bone complications and other SCD-related symptoms.
- Complete Blood Count and Peripheral Blood Assessment: A complete blood count evaluates hemoglobin, red blood cells, white blood cells and platelets. A peripheral blood smear can provide information about red-cell morphology and other blood abnormalities associated with SCD.
- Hemoglobin Analysis: Hemoglobin electrophoresis, high-performance liquid chromatography or other specialised testing can identify abnormal hemoglobin types and help determine the specific SCD genotype or hemoglobinopathy.
- Assessment of Organ Complications: Depending on age and symptoms, evaluation may include kidney function and urine testing, liver assessment, pulmonary evaluation, eye examination and neurological assessment.
- Genetic and Family Assessment: Genetic counselling and testing may help clarify the inherited hemoglobin pattern and provide information about reproductive risks and family screening.
- Imaging Tests:
- Transcranial Doppler Ultrasound: Used particularly in children with SCD to assess cerebral blood-flow velocities and help identify increased stroke risk.
- Brain MRI and MRA: May be recommended when neurological symptoms, previous stroke or silent cerebral injury is suspected.
- Chest X-ray: May be used when acute chest syndrome, pneumonia or another chest complication is suspected.
- Echocardiography: May be used to evaluate cardiac structure and function when clinically indicated.
- Ultrasound or MRI: May help evaluate abdominal, bone or other organ complications depending on symptoms.
- Retinal Imaging: Ophthalmologic imaging can detect sickle-cell-related retinal changes.
MediRehab (a chain of Rehab centres, part of MediGence) provides comprehensive rehabilitation services designed to support Sickle Cell Disease (SCD) patients in India. These services include:
- Physical Activity and Exercise: Individualised physical activity can help maintain strength, mobility and cardiovascular fitness, with intensity adjusted according to anemia, pain, organ complications and overall health.
- Pain and Mobility Rehabilitation: Physiotherapy may help patients manage chronic musculoskeletal pain, maintain joint mobility and improve functional movement while avoiding activities that worsen symptoms.
- Fatigue and Energy Management: Structured activity planning, appropriate rest, sleep support and treatment of underlying anemia can help patients manage chronic fatigue and maintain daily activities.
- Psychological and Self-Management Support: Counselling, patient education and chronic-pain support can help patients cope with recurrent crises, treatment demands, school or work limitations and the emotional effects of living with a chronic blood disorder.
- Medicines for SCD aim to reduce sickling, prevent complications and manage acute symptoms. Hydroxyurea is an established disease-modifying medicine that can increase fetal hemoglobin and reduce the frequency of pain crises in appropriate patients. Other medicines may be used for pain management and selected disease-related complications. Patients receiving regular transfusions may require treatment and monitoring for iron overload.
Instantly Connect with our Specialists
Hospitals for Sickle Cell Disease (SCD) in India
Batra Hospital
Delhi, India
- More than 35 years of trusted healthcare service
- Multi-specialty tertiary care with over 30 departments
- Comprehensive preventive, diagnostic, and therapeutic care under one roof
- International patient coordination team for seamless overseas care
Marengo Asia Hospitals, Gurugram
Gurgaon, India
- Marengo Asia Hospitals, Gurugram, is a 250-bed multi-speciality tertiary care hospital, formerly known as W Pratiksha Hospital.
- A major medical centre for Delhi NCR and North India, it is situated on Golf Course Extension Road, Sector 56, Gurugram.
- The hospital's NABH and NABL accreditation ensures compliance with international standards for patient care, safety, and quality.
- Provides extensive medical care in more than 21 specialities, including as women's health, neurology, orthopaedics, cardiology, and cancer.
- Advanced robotic-assisted spine surgery tools and neuro-monitoring technology are available at the Marengo Asia International Institute of Neuro & Spine (MAIINS), a Centre of Excellence in Neurosciences.
- Equipped with cutting-edge equipment, such as automated labs, sophisticated imaging, and contemporary operating rooms.
- Features specialised ICUs, NICUs, and modular OTs built for complex and minimally invasive procedures.
Jaslok Hospital & Research Center
Mumbai, India
- Jaslok Hospital & Research Centre, Mumbai, is a 350-bed super-speciality tertiary care hospital, established in 1973 and among India’s most respected private trust hospitals.
- Located on Peddar Road in South Mumbai, overlooking the Arabian Sea, it serves as a major referral centre for Mumbai, Maharashtra, and patients from across India and abroad.
- The hospital offers comprehensive care across 50+ specialities and nearly 20 multidisciplinary speciality clinics, addressing complex and advanced medical conditions.
- Supported by 300+ senior consultants and 200 resident doctors, ensuring high standards of expertise and round-the-clock patient care.
- Equipped with 75 ICU beds, advanced critical care units, modular operation theatres, and state-of-the-art diagnostic and imaging facilities.
- Recognised as a leading centre of excellence in Critical Care, Cardiac Sciences, Neurosciences, Oncosciences, Renal Sciences, Gastroenterology, and Assisted Reproduction.
- A prominent research and academic institution, conducting clinical trials and recognised by the National Board of Examinations (NBE) in 22 specialities.
- Strong emphasis on quality, patient safety, and evidence-based care, with continuous monitoring of clinical and operational outcomes to meet international healthcare standards.
Our Services to better your experience
Opinion & Option
We submit the most accurate opinion and options from one or more countries for your review
Consult Privately
Consult with a certified specialist privately on our telemedicine platform even before you decide to travel
Logistics
We handle flights, visas, transfers, and accommodation—so you can focus on your health.
Recovery
Our In-house rehabilitation service packages to better your recovery and treatment outcome
Why Choose India for Sickle Cell Disease (SCD) Treatment?
- Multidisciplinary Hematology Care: Patients can access hematologists, pediatric hematologists, transfusion specialists, genetic counsellors and other specialists according to their needs.
- Advanced Diagnostic Facilities: Specialised centres may provide hemoglobin analysis, genetic testing, blood-count monitoring, organ-function assessment and imaging for SCD-related complications.
- Comprehensive Disease Management: Treatment can include hydroxyurea, pain management, transfusion programmes, vaccination and monitoring for organ complications.
- Stem-Cell Transplantation: Major transplant centres can evaluate eligible patients for allogeneic hematopoietic stem-cell transplantation and provide donor assessment and post-transplant monitoring.
- Advanced Cellular and Gene-Based Therapies: Specialised centres may provide access to emerging cellular or gene-based treatment programmes where regulatory approval, clinical eligibility and infrastructure permit.
Frequently Asked Questions
Sickle cell disease is a lifelong inherited condition, not an illness with a fixed recovery period. Individual pain crises may resolve over hours or days with appropriate treatment, while chronic complications require ongoing management. Selected patients undergoing stem-cell transplantation or gene therapy may have a prolonged treatment and recovery period.
Yes. Most people with SCD can walk and remain physically active. However, severe anemia, pain, bone or joint complications and other health problems may affect mobility. Adjust physical activity based on symptoms and guidance from the treating healthcare team.
Major Indian hematology centres may provide hemoglobin analysis, genetic testing, transfusion services, advanced imaging, stroke-risk screening, hydroxyurea-based treatment and hematopoietic stem-cell transplantation. Selected specialised centres may also participate in advanced cellular or gene-therapy programmes.
Many major Indian hospitals have international-patient departments that can assist with medical records, specialist consultations, treatment coordination, travel arrangements, accommodation and follow-up care.
Consider a centre with experienced hematologists and access to comprehensive SCD care, including blood transfusion services, genetic testing, management of acute and chronic complications and multidisciplinary support. If you are considering curative treatment, evaluate the centre's experience with hematopoietic stem-cell transplantation and access to appropriate specialised therapies.
There is no single success rate for SCD treatment. Outcomes depend on the disease genotype, age, frequency of complications, organ health, treatment response and the type of therapy used. Disease-modifying treatment can reduce complications in appropriate patients, while stem-cell transplantation and certain gene therapies may offer potentially curative treatment for selected patients.
Hematologists and pediatric hematologists at specialised Indian centres manage SCD, including pain crises, anemia, transfusion requirements, stroke prevention, organ complications and disease-modifying treatment. Patients considering transplantation or advanced cellular therapies should consider centres with relevant specialist experience.
Treatment risks depend on the therapy used. Hydroxyurea and other medicines can cause treatment-specific adverse effects and require monitoring. Blood transfusions can cause reactions, alloimmunisation and iron overload. Stem-cell transplantation carries risks including infections, graft-versus-host disease and other transplant-related complications. Gene therapies require intensive conditioning and specialised cell-based treatment and may also carry serious risks that require long-term monitoring.
A suspected vaso-occlusive pain crisis or other new SCD complication should be assessed promptly, particularly when pain is severe or unusual. Fever, difficulty breathing, chest pain, sudden weakness, confusion, severe headache, vision changes or other neurological symptoms require urgent medical attention because they may indicate serious complications.
SCD does not typically cause structural deformities by itself, but repeated vaso-occlusive events and chronic anemia can contribute to bone and joint damage, growth problems and other long-term complications. Early and comprehensive management can help reduce the risk of preventable complications.
Yes. Recurrent pain crises, fatigue, hospital visits, anemia, treatment requirements and chronic organ complications can affect physical activity, education, employment, sleep and emotional well-being. Comprehensive disease management and appropriate psychosocial support can help patients maintain independence and daily functioning.
Yes. Untreated or inadequately managed SCD can cause recurrent pain crises and progressive complications affecting the brain, lungs, kidneys, eyes, bones, heart and other organs. Severe complications can include stroke, acute chest syndrome, severe anemia, infections and chronic organ damage.
SCD is an inherited genetic condition and cannot be prevented after a person inherits the disease-causing variants. However, carrier screening and genetic counselling can help individuals and couples understand their reproductive risks. For people living with SCD, preventive healthcare, vaccinations, prescribed medicines, regular monitoring and avoidance of known triggers can help reduce complications.
SCD is more common in populations with ancestry from regions where the sickle hemoglobin gene is more prevalent, including parts of Africa, the Middle East, the Mediterranean and South Asia. In India, sickle cell disease is particularly relevant in several tribal and other communities. Because SCD is inherited, having parents who carry disease-causing hemoglobin variants increases the likelihood of inheriting the condition.